This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kreipe, H. Articles by Parwaresch, R. Search for Related Content PubMed PubMed Citation Articles by Kreipe, H. Articles by Parwaresch, R.

American Journal of Pathology, Vol 142, 651-657, Copyright © 1993 by American Society for Investigative Pathology

REGULAR ARTICLES

Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1

H Kreipe, P Alm, H Olsson, M Hauberg, L Fischer and R Parwaresch
Institute of Pathology, Kiel, Germany.

Proliferative activity is a potential prognostic indicator of neoplastic cell growth. Usually the assessment of the tumor growth fraction requires specially processed or frozen tissue. We have raised a monoclonal antibody, Ki-S1, suitable for the detection of proliferating cells in routinely processed and paraffin-embedded tissue specimens. A retrospective study was conducted on 83 mammary carcinoma patients with a median follow-up of 45.6 months. Ki-S1 positivity was significantly (P < 0.0001) correlated with the S-phase fraction. A high proliferative activity of more than 30% of tumor cells being Ki-S1- positive was significantly correlated with recurrence (P < 0.001). Cumulative survival was significantly reduced in the high Ki-S1 expressing subgroup. In a multivariate model including Ki-S1, lymph node metastases, tumor size, and progesterone receptor positivity, independent significant information was provided by Ki-S1. We conclude that in mammary carcinomas, Ki-S1-determined growth fraction represents a significant and independent prognostic predictor.

This article has been cited by other articles:

				I. A. Doussis-Anagnostopoulou, T. P. Vassilakopoulos, I. Thymara, P. Korkolopoulou, M. K. Angelopoulou, M. P. Siakantaris, S. I. Kokoris, E. M. Dimitriadou, C. Kalpadakis, M. Matzouranis, et al. Topoisomerase II{alpha} Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma Clin. Cancer Res., March 15, 2008; 14(6): 1759 - 1766. [Abstract] [Full Text] [PDF]

				A.-M. C. Dingemans, M. A. Witlox, R. A. L. M. Stallaert, P. van der Valk, P. E. Postmus, and G. Giaccone Expression of DNA Topoisomerase II{{alpha}} and Topoisomerase II{beta} Genes Predicts Survival and Response to Chemotherapy in Patients with Small Cell Lung Cancer Clin. Cancer Res., August 1, 1999; 5(8): 2048 - 2058. [Abstract] [Full Text] [PDF]

				P. Rudolph, P. Alm, H.-J. Heidebrecht, H. Bolte, V. Ratjen, B. Baldetorp, M. Ferno, H. Olsson, and R. Parwaresch Immunologic Proliferation Marker Ki-S2 as Prognostic Indicator for Lymph Node-Negative Breast Cancer J Natl Cancer Inst, February 3, 1999; 91(3): 271 - 278. [Abstract] [Full Text] [PDF]

				H.J. Heidebrecht, F. Buck, J. Steinmann, R. Sprenger, H.H. Wacker, and R. Parwaresch p100: A Novel Proliferation-Associated Nuclear Protein Specifically Restricted to Cell Cycle Phases S, G2 , and M Blood, July 1, 1997; 90(1): 226 - 233. [Abstract] [Full Text] [PDF]

				U. Kellner, H.-J. Heidebrecht, P. Rudolph, H. Biersack, F. Buck, T. Dakowski, H.-H. Wacker, M. Domanowski, A. Seidel, O. Westergaard, et al. Detection of Human Topoisomerase II{alpha} in Cell Lines and Tissues: Characterization of Five Novel Monoclonal Antibodies J. Histochem. Cytochem., February 1, 1997; 45(2): 251 - 264. [Abstract] [Full Text] [PDF]